Director at Edgewise Therapeutics (EWTX) awarded 339 new shares

Rhea-AI Filing Summary

Edgewise Therapeutics, Inc. director Jonathan C. Fox received a grant of 339 shares of Common Stock as a stock award. The shares were acquired at no cash cost to him and increase his direct ownership to 24,514 shares following the transaction on April 1, 2026.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Fox Jonathan C

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	339	$0.00	--

Holdings After Transaction: Common Stock — 24,514 shares (Direct)

Footnotes (1)

Key Figures

Shares granted: 339 shares Price per granted share: $0.00 per share Shares held after transaction: 24,514 shares

3 metrics

Shares granted 339 shares Stock award to director on April 1, 2026

Price per granted share $0.00 per share Compensation grant, not open-market purchase

Shares held after transaction 24,514 shares Director’s direct Common Stock holdings after grant

Key Terms

Common Stock, Grant, award, or other acquisition, Form 4

3 terms

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fox Jonathan C

(Last) (First) (Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		A		339	A	$0.00	24,514	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Consists of restricted stock units granted and released to the reporting person on April 1, 2026, as a Quarterly Retainer Award pursuant to Section 2.4 of the Edgewise Therapeutics, Inc. Outside Director Compensation Policy, as amended.

	/s/ John R. Moore, Attorney-in-Fact for Fox Jonathan C	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Edgewise Therapeutics (EWTX) director Jonathan C. Fox report on this Form 4?

Jonathan C. Fox reported receiving a grant of 339 shares of Edgewise Therapeutics Common Stock. This was a stock award recorded at a price of $0.00 per share and reflects a compensation-related share issuance, not an open-market purchase or sale.

How many Edgewise Therapeutics (EWTX) shares does Jonathan C. Fox hold after this grant?

After the 339-share grant, Jonathan C. Fox directly holds 24,514 shares of Edgewise Therapeutics Common Stock. This total reflects his direct ownership position reported in the filing immediately following the April 1, 2026 stock award transaction.

Was cash paid for the 339-share grant to the Edgewise Therapeutics director?

No cash was paid for the 339-share grant; it was recorded at $0.00 per share. This indicates the shares were awarded as compensation rather than purchased in the open market, consistent with a grant, award, or other acquisition entry.

Is the Edgewise Therapeutics (EWTX) Form 4 transaction a buy or a compensation grant?

The transaction is a compensation grant, not an open-market buy. The filing labels the code as a grant, award, or other acquisition, and the 339 shares were acquired at $0.00 per share, indicating they were issued as part of director compensation.

Does the Form 4 for Edgewise Therapeutics disclose any stock option exercises?

The filing does not report any stock option exercises. It shows a single non-derivative transaction where 339 shares of Common Stock were granted, and the derivative section contains no remaining options or other derivative positions for this reporting person.